Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT ...

A recent study by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the ...

OBJECTIVES Charcot-Marie-Tooth disease type I (CMT1) is a hereditary sensorimotor neuropathy causing variable degrees of handicap. The risk for relevant disability in respect to genetic counselling is ...

SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...

Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...

An east Auckland teenager with a rare genetic condition is grateful for having received equipment that will make it easier ...

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

In this article, we focus on the importance of early recognition of joint changes in these patients in order to prevent irreversible joint loss. In 1868, the French neurologist Jean-Marie Charcot ...

Jackson will perform at the world’s largest outdoor honky-tonk on April 5 - his last appearance in the Austin area of Texas.

The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants ...

Alan Jackson's next farewell tour concert is on Saturday, Nov. 16, 2024, in Salt Lake City, Utah. In this file photo, he ...